National Survey on Asthma - Full Text View

National Survey on Asthma (SYMPTOMES)

This study is currently recruiting participants.

Verified by AstraZeneca, October 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00770250

Purpose

To evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control.

Condition
Asthma

MedlinePlus related topics: Asthma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional
Official Title:	A Mirror Assessment of the Words Used By Patients and Physicians to Express Asthma Symptoms, According To the Patient's Level of Asthma Control In General Medicine

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

The concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control. [ Time Frame: Once ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	2000
Study Start Date:	October 2008
Estimated Study Completion Date:	January 2009

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

The first 2 consecutive patients seen during the GP's visit with a diagnosis of persistent asthma

Criteria

Inclusion Criteria:

A diagnosis of persistent asthma treated with an inhaled corticosteroid based maintenance treatment for more than 3 months
Given his/her consent to participate to the study and who is able to answer the questionnaire in french by him/her-self.

Exclusion Criteria:

Patient with a cardiac disease (congestive heart failure, coronary artery disease)
Patient with a respiratory disease other than asthma (COPD, sleep apnea syndrome).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00770250

Contacts

Contact: AstraZeneca France Clinical Study Information

01 41 29 40 00

stephan.becouarn@astrazeneca.com

Show 910 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Alain Castaigne

AstraZeneca

More Information

Responsible Party:	AstraZeneca Pharmaceuticals ( Alain Castaigne, Medical Director )
Study ID Numbers:	NIS-RFR-DUM-2008/1
Study First Received:	October 7, 2008
Last Updated:	October 8, 2008
ClinicalTrials.gov Identifier:	NCT00770250
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

asthma symptoms
words used by patients and physicians
express asthma symptoms

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009